A Bayesian design for phase I cancer therapeutic vaccine trials
Wang, Rosner and Roden – 2019 (view in PDF)...
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
- Seeking Series B investment for next phase of clinical trials
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
News & Articles
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
van Poelgeest e al – 2013 (view in PDF)...
ELISpot for measuring human immune responses to vaccines
Slota et al – 2011 (view in PDF)...
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation
Rosalia et al – 2013 (view in PDF)...
Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells
Rabu C et al, Oncoimmunology 2019 (view in PDF)...
T cell responses: naïve to memory and everything in between
Pennock et al – 2013 (view in PDF)...
Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
Mougel, Terme and Tanchot – 2019 (view in PDF)...
Contact Us
If you have any questions or want to get in touch, please contact our team.
(c) 2025 Oxford Vacmedix UK Limited | Company Registration: 07994205
English